The effects of Ibupropen on term infants arterial duct

The Effect of oral Ibuprofen in term Infants with Patent Dactus Arteriosus

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190204042618N1

Enrollment

Registered

2019-02-15

Start date

2018-07-11

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent Dactus Arteriosus. Patent ductus arteriosus

Interventions

Intervention 1: Intervention group: reciving Ibuprofen, as an oral aqueous suspension (100 mg/5 ml

Alborz pharmaceutical) with a dose of 10 mg/kg at the beginning and four doses of 5 mg/kg with 24 hours intervals. Intervention 2: Control group: reciving no drug.

Eligibility

Sex/Gender

All

Age

5 Days to 30 Days

Inclusion criteria

Inclusion criteria: Gestational age more than 37 weeks Age between 5 and 30 days old Patent dactus arteriosus size more than 1.5 mm detected by echocardiography

Exclusion criteria

Exclusion criteria: Having ductal dependent congenital heart disease Creatinine more than 88.5 micromol/l Platelet count less than 50000

Design outcomes

Primary

Measure	Time frame
Patent Dactus Arteriosus closure. Timepoint: Day one, Day 7 after intervention. Method of measurement: Eco cardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nabi Allah Asadpour

Shahre-kord University of Medical Sciences

n.asadpour@skums.ac.ir+98 38 3224 8235

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026